학술논문
Single dose moxidectin versus ivermectin for Onchocerca volvulusinfection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial
Document Type
Article
Author
Opoku, Nicholas O; Bakajika, Didier K; Kanza, Eric M; Howard, Hayford; Mambandu, Germain L; Nyathirombo, Amos; Nigo, Maurice M; Kasonia, Kambale; Masembe, Safari L; Mumbere, Mupenzi; Kataliko, Kambale; Larbelee, Jemmah P; Kpawor, Mawolo; Bolay, Kpehe M; Bolay, Fatorma; Asare, Sampson; Attah, Simon K; Olipoh, George; Vaillant, Michel; Halleux, Christine M; Kuesel, Annette C
Source
The Lancet; October 2018, Vol. 392 Issue: 10154 p1207-1216, 10p
Subject
Language
ISSN
01406736; 1474547X
Abstract
The morbidity and socioeconomic effects of onchocerciasis, a parasitic disease that is primarily endemic in sub-Saharan Africa, have motivated large morbidity and transmission control programmes. Annual community-directed ivermectin treatment has substantially reduced prevalence. Elimination requires intensified efforts, including more efficacious treatments. We compared parasitological efficacy and safety of moxidectin and ivermectin.